TGFB1 and central nervous system cancer: Using a mouse model, a TGF-β1–SLUG activation axis was recently shown to promote a pro-mesenchymal phenotype of glioma cells and a subsequent trans-differentiation towards a therapy-resistant state in vivo, thus demonstrating the functional involvement of SLUG as a driver of recurrence in GBMs [26].